MedTrace Logo

Effect of Potassium Bicarbonate Supplementation on Bone and Muscle in Older Adults

NCT00357214 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 171

Last updated 2020-02-17

Study results available
· View outcomes & findings →

Summary

There is increasing evidence that the acid-base balance of diet plays an important role in the health of bones and muscles. An excess of acid in the body can result in calcium loss and muscle breakdown. Potassium bicarbonate, a base supplement, can neutralize acid within the body. The purpose of this study is to determine the effectiveness of potassium and bicarbonate, alone and combined, at reducing bone loss and preventing muscle wasting in older adults.

Conditions

Interventions

DIETARY_SUPPLEMENT

Potassium Bicarbonate

67.5 mmol/d given as three tablets after each meal, with a full glass of water

DIETARY_SUPPLEMENT

Sodium Bicarbonate

67.5 mmol/d given as three tablets after each meal, with a full glass of water

DIETARY_SUPPLEMENT

Potassium Chloride

67.5 mmol/d given as three tablets after each meal, with a full glass of water

DIETARY_SUPPLEMENT

placebo (microcrystalline cellulose)

Given as three tablets after each meal, with a full glass of water

Sponsors & Collaborators

  • National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

    collaborator NIH

  • Tufts University

    lead OTHER

Principal Investigators

  • Bess Dawson-Hughes, MD · Tufts Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-09-30
Primary Completion
2008-04-30
Completion
2008-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00357214 on ClinicalTrials.gov